| NCT06540729 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Ovary Cancer | 2024-09-24 | PHASE2 |
| NCT06378242 | RemeGen Co., Ltd. | High-risk Non-muscle Invasive Bladder Cancer | 2024-06-14 | PHASE1|PHASE2 |
| NCT06650332 | Zhejiang Cancer Hospital | Metastatic HER2 Positive Gastroesophageal Junction Cancer | 2024-07-10 | PHASE1|PHASE2 |
| NCT06660511 | Second Xiangya Hospital of Central South University | Ovarian Cancer Recurrent | 2024-10-15 | EARLY_PHASE1 |
| NCT06791070 | Fujian Medical University Union Hospital|Zhejiang Tumor Hospital|Fujian Provincial Hospital|Zhangzhou Affiliated Hospital of Fujian Medical University|Quanzhou First Hospital|First Affiliated Hospital of Wenzhou Medical University | Paget Disease, Extramammary|Scrotum Disease | 2025-01 | PHASE2 |
| NCT05912205 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Urothelial Carcinoma | 2023-07-01 | PHASE2 |
| NCT05940896 | RemeGen Co., Ltd. | Solid Tumor | 2023-06-29 | PHASE1 |
| NCT07117851 | Fudan University|Fujian Province Tumor Hospital|Qinghai Province Fifth People´s Hospital | Extramammary Paget Disease|Scrotum Disease | 2025-08-01 | PHASE2 |
| NCT06078982 | Shanghai East Hospital | Gastric Cancer|HER2-low-expressing Gastric Cancer | 2023-06-06 | PHASE1 |
| NCT05586061 | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer | 2023-02-10 | PHASE2 |
| NCT05333809 | Shanghai Zhongshan Hospital | Colorectal Neoplasms | 2022-07-01 | PHASE2 |
| NCT05911295 | Seagen, a wholly owned subsidiary of Pfizer|RemeGen Co., Ltd.|Merck Sharp & Dohme LLC | Urothelial Carcinoma | 2023-09-22 | PHASE3 |
| NCT06560528 | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer|Gastroesophageal Junction Adenocarcinoma | 2024-09-01 | PHASE2 |
| NCT06957561 | Sun Yat-sen University | Bladder Cancer|Muscle-invasive Bladder Cancer | 2025-04-30 | PHASE1|PHASE2 |
| NCT06227156 | RemeGen Co., Ltd. | Castration-resistant Prostate Cancer | 2024-04-08 | PHASE2 |
| NCT06278870 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Metastatic Breast Cancer|First-line Treatment | 2023-09-06 | PHASE3 |
| NCT06487429 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|RemeGen Co., Ltd. | Gastric Cancer | 2024-05-08 | PHASE2 |
| NCT05851677 | RenJi Hospital | Breast Cancer | 2023-06-01 | |
| NCT06904573 | Sun Yat-sen University | Advanced Urothelial Carcinoma|Probiotics|Immunotherapy | 2025-01-01 | PHASE2 |
| NCT05649163 | Shen Lin|RemeGen Co., Ltd. | HER2|Advanced Gastric Cancer|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Solid Tumor | 2023-01 | |
| NCT05928897 | Xiangya Hospital of Central South University | Gastric Cancer | 2023-07-01 | PHASE2 |
| NCT06185400 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non Small Cell Lung Cancer|ERBB2 Mutation-Related Tumors|ERBB2 Gene Duplication|Disitamab Vedotin | 2024-02-01 | PHASE2 |
| NCT06000033 | Qilu Hospital of Shandong University | Breast Cancer | 2023-08-10 | PHASE2 |
| NCT06227117 | RemeGen Co., Ltd. | Breast Cancer | 2023-07-27 | PHASE2 |
| NCT06730373 | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer|Metastatic Gastric Cancer|Unresectable Gastric Carcinoma | 2024-10-17 | PHASE2 |
| NCT05861635 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Breast Cancer|Neoadjuvant Therapy | 2023-02-01 | PHASE4 |
| NCT05113459 | Guoxin Li | Gastric Cancer | 2021-12-18 | PHASE2 |
| NCT06221748 | RemeGen Co., Ltd. | Gastric Cancer|Gastroesophageal Junction Adenocarcinoma | 2024-02-22 | PHASE2|PHASE3 |
| NCT07315750 | RemeGen Co., Ltd. | Gastric Carcinoma | 2026-01-01 | PHASE3 |
| NCT07159217 | Peking Union Medical College Hospital | Biliary Tract Cancer|Disitamab Vedotin|Lenvatinib|Immune Checkpoint Inhibitors | 2025-08-30 | PHASE2 |
| NCT05955209 | Peking University Cancer Hospital & Institute | Metastatic Castration-resistant Prostate Cancer | 2023-08-01 | PHASE2 |
| NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer|RemeGen Co., Ltd. | Breast Neoplasms|Gastroesophageal Junction Adenocarcinoma|HER2 Low Breast Neoplasms|HER2 Positive Breast Neoplasms|Stomach Neoplasms|Triple Negative Breast Neoplasms|Metastatic Breast Cancer|Metastatic Gastric Cancer|Advanced Breast Cancer|Advanced Gastric Cancer | 2024-05-20 | PHASE2 |
| NCT06492317 | The First Affiliated Hospital of Zhengzhou University | HER2-positive Gastric Cancer | 2024-07-06 | PHASE2 |
| NCT06944496 | RemeGen Co., Ltd. | Gastric Carcinoma | 2025-05-15 | PHASE3 |
| NCT05979740 | RenJi Hospital | Muscle Invasive Bladder Cancer|HER2 Expression|Radiotherapy|PD-1|Antibody-drug Conjugates | 2023-08-01 | PHASE2 |
| NCT06187506 | Fudan University | Non-muscle Invasive Bladder Cancer|HER-2 Protein Overexpression | 2023-12-18 | PHASE2 |
| NCT07142200 | RenJi Hospital | Bladder (Urothelial, Transitional Cell) Cancer | 2025-09-01 | PHASE2 |
| NCT06015113 | Xi´an International Medical Center Hospital | Breast Cancer | 2023-09 | NA |
| NCT05495724 | Tianjin Medical University Second Hospital | Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | 2021-07-23 | PHASE2 |
| NCT07366840 | Fudan University | HER2-positive Breast Cancer|Metastatic Breast Cancer | 2026-01-16 | PHASE2|PHASE3 |
| NCT07446452 | The First Affiliated Hospital with Nanjing Medical University|RenJi Hospital|Anhui Provincial Hospital|The Affiliated Hospital of Xuzhou Medical University|The First Hospital of Jilin University|Shanghai Minhang Central Hospital|Zhejiang Cancer Hospital|Huai´an First People´s Hospital | HER2-low Breast Cancer | 2024-01-01 | PHASE2 |
| NCT06003231 | Seagen, a wholly owned subsidiary of Pfizer | Carcinoma, Non-Small-Cell Lung|Ovarian Neoplasms|Endometrial Neoplasms|Head and Neck Neoplasms | 2023-11-14 | PHASE2 |
| NCT07093866 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Nanjing University | mCRPC | 2025-07-20 | PHASE2 |
| NCT06155383 | RemeGen Co., Ltd. | Gastric Cancer|Gastroesophageal Junction Adenocarcinoma | 2023-11-27 | PHASE2 |
| NCT05723991 | Chunguang yang (101937) | Radical Cystectomy|Urothelial Carcinoma | 2022-09-28 | PHASE4 |
| NCT07100184 | Peking University First Hospital|RemeGen Co., Ltd. | HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT | 2025-09-01 | PHASE2 |
| NCT06155396 | RemeGen Co., Ltd. | Cervical Cancer | 2024-01-11 | PHASE2 |
| NCT06558682 | Qilu Hospital of Shandong University|RemeGen Co., Ltd. | Uterine Cervical Neoplasms | 2024-10-20 | NA |
| NCT05831878 | RenJi Hospital | Advanced Breast Cancer | 2023-05-04 | NA |
| NCT06233864 | Sun Yat-sen University | Pancreatic Cancer | 2024-04-17 | PHASE2 |
| NCT05726175 | West China Hospital | Breast Cancer | 2023-03-01 | PHASE2 |
| NCT06383533 | Zhejiang Cancer Hospital | Bile Duct Adenocarcinoma Non-Resectable|HER2 Gene Mutation | 2023-05-01 | PHASE2 |
| NCT06572319 | Zhejiang Cancer Hospital | HER2-positive Gastric Cancer|HER2-positive Gastroesophageal Junction Adenocarcinoma | 2024-09-01 | PHASE1|PHASE2 |
| NCT06389006 | RemeGen Co., Ltd. | Breast Cancer | 2024-04-29 | PHASE2 |
| NCT07474064 | chenxu | Muscle Invasive Bladder Cancer (MIBC) | 2026-03-26 | PHASE2 |
| NCT05627414 | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 2023-01-01 | PHASE2 |
| NCT06105008 | RemeGen Co., Ltd. | Breast Neoplasms | 2024-12-20 | PHASE2 |
| NCT05540483 | The First Affiliated Hospital with Nanjing Medical University | Biliary Carcinoma | 2022-08-01 | NA |
| NCT07194005 | Fudan University | Gastric Cancer | 2025-09-04 | PHASE2 |
| NCT05720533 | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 2023-03-01 | PHASE2 |
| NCT05982834 | Fudan University | HER2-positive Gastric Cancer|Immunotherapy | 2023-05-09 | PHASE1|PHASE2 |
| NCT07509424 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Rectal Cancer | 2026-04-22 | PHASE2 |
| NCT05488353 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Nanfang Hospital, Southern Medical University|Southern Medical University, China|The Third Affiliated Hospital of Southern Medical University | Bladder Cancer | 2022-09-01 | PHASE4 |
| NCT06749860 | Shanghai Pulmonary Hospital, Shanghai, China | Lung Cancer | 2024-02-02 | PHASE2 |
| NCT07490990 | West China Hospital|Jiangsu Taizhou People´s Hospital|Chengdu First People´s Hospital | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | 2026-06 | |
| NCT04879329 | Seagen, a wholly owned subsidiary of Pfizer|Merck Sharp & Dohme LLC | Urothelial Carcinoma | 2022-05-03 | PHASE2 |
| NCT07498907 | Peking University First Hospital|RemeGen Co., Ltd. | Upper Tract Urothelial Carcinoma | 2026-05-01 | PHASE2 |
| NCT05661357 | Zhongnan Hospital|Huangshi Central Hospital|The First People´s Hospital of Tianmen|Sir Run Run Shaw Hospital|Hubei Cancer Hospital | HER2|Colorectal Cancer | 2023-01-01 | PHASE4 |
| NCT06734182 | Guangdong Provincial People´s Hospital | Non-small Cell Lung Cancer | 2024-06-22 | PHASE2 |
| NCT07065435 | The First Affiliated Hospital with Nanjing Medical University|RenJi Hospital|Anhui Provincial Hospital|The Affiliated Hospital of Xuzhou Medical University|The First Hospital of Jilin University|Shanghai Minhang Central Hospital|Zhejiang Cancer Hospital|Huai´an First People´s Hospital | HER2 &addition; Breast Cancer | 2024-01-01 | PHASE2 |
| NCT06210490 | Peking University First Hospital | Upper Urinary Tract Urothelial Carcinoma | 2024-02-20 | PHASE2 |
| NCT05493683 | The First Affiliated Hospital with Nanjing Medical University | Colorectal Neoplasms | 2022-08-01 | PHASE2 |
| NCT05904964 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HR Positive+HER2 Low Expression Metastatic Breast Cancer | 2023-07-01 | PHASE3 |